readthroughSign in
Nov 12, 2026Regulatory decision

FDA grants accelerated approval to ponatinib combination for Ph+ ALL

The agency cleared Iclusig with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia on March 19, 2024.

The Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia on March 19, 2024.1

The approval covers patients newly diagnosed with this subtype of acute lymphoblastic leukemia, a blood cancer marked by the presence of the Philadelphia chromosome, and pairs the targeted therapy ponatinib with standard chemotherapy regimens.

As this is an accelerated approval, it is typically contingent on confirmatory trial data to verify the clinical benefit, though the specific confirmatory requirements are not detailed in the available record. Readers seeking full prescribing information, dosing details, or the clinical trial results underpinning this authorization should consult Takeda's official labeling and the FDA's complete approval announcement, as the source record provided here contains only the top-line approval notice.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.